84 related articles for article (PubMed ID: 23568716)
1. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.
Rubinson DA; Hochster HS; Ryan DP; Wolpin BM; McCleary NJ; Abrams TA; Chan JA; Iqbal S; Lenz HJ; Lim D; Rose J; Bekaii-Saab T; Chen HX; Fuchs CS; Ng K
Invest New Drugs; 2014 Feb; 32(1):113-22. PubMed ID: 23568716
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
Spiekman IAC; Zeverijn LJ; Geurts BS; Verkerk K; Haj Mohammad SF; van der Noort V; Roepman P; de Leng WWJ; Jansen AML; Gootjes EC; de Groot DA; Kerver ED; van Voorthuizen T; Roodhart JML; Valkenburg-van Iersel LBJ; Gelderblom H; Voest EE; Verheul HMW
Eur J Cancer; 2024 May; 202():113988. PubMed ID: 38471288
[TBL] [Abstract][Full Text] [Related]
4. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Gianni L; Lladó A; Bianchi G; Cortes J; Kellokumpu-Lehtinen PL; Cameron DA; Miles D; Salvagni S; Wardley A; Goeminne JC; Hersberger V; Baselga J
J Clin Oncol; 2010 Mar; 28(7):1131-7. PubMed ID: 20124183
[TBL] [Abstract][Full Text] [Related]
5. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
6. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.
Seo AN; Kwak Y; Kim DW; Kang SB; Choe G; Kim WH; Lee HS
PLoS One; 2014; 9(5):e98528. PubMed ID: 24879338
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Ng K; Tabernero J; Hwang J; Bajetta E; Sharma S; Del Prete SA; Arrowsmith ER; Ryan DP; Sedova M; Jin J; Malek K; Fuchs CS
Clin Cancer Res; 2013 Jul; 19(14):3987-95. PubMed ID: 23743569
[TBL] [Abstract][Full Text] [Related]
9. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F; Hurwitz H; Raghav KPS; McWilliams RR; Fakih M; VanderWalde A; Swanton C; Kurzrock R; Burris H; Sweeney C; Bose R; Spigel DR; Beattie MS; Blotner S; Stone A; Schulze K; Cuchelkar V; Hainsworth J
Lancet Oncol; 2019 Apr; 20(4):518-530. PubMed ID: 30857956
[TBL] [Abstract][Full Text] [Related]
12. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
Shitara K; Yamanaka T; Denda T; Tsuji Y; Shinozaki K; Komatsu Y; Kobayashi Y; Furuse J; Okuda H; Asayama M; Akiyoshi K; Kagawa Y; Kato T; Oki E; Ando T; Hagiwara Y; Ohashi Y; Yoshino T
Ann Oncol; 2019 Feb; 30(2):259-265. PubMed ID: 30508156
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line
Hill AG; Findlay MP; Burge ME; Jackson C; Alfonso PG; Samuel L; Ganju V; Karthaus M; Amatu A; Jeffery M; Bartolomeo MD; Bridgewater J; Coveler AL; Hidalgo M; Kapp AV; Sufan RI; McCall BB; Hanley WD; Penuel EM; Pirzkall A; Tabernero J
Clin Cancer Res; 2018 May; 24(10):2276-2284. PubMed ID: 29506988
[No Abstract] [Full Text] [Related]
14. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.
Sartore-Bianchi A; Amatu A; Bonazzina E; Stabile S; Giannetta L; Cerea G; Schiavetto I; Bencardino K; Funaioli C; Ricotta R; Cipani T; Schirru M; Gambi V; Palmeri L; Carlo-Stella G; Rusconi F; Di Bella S; Burrafato G; Cassingena A; Valtorta E; Lauricella C; Pazzi F; Gambaro A; Ghezzi S; Marrapese G; Tarenzi E; Veronese S; Truini M; Vanzulli A; Siena S
Target Oncol; 2017 Aug; 12(4):525-533. PubMed ID: 28669023
[TBL] [Abstract][Full Text] [Related]
15. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E; Martino C; Sartore-Bianchi A; Penaullt-Llorca F; Viale G; Risio M; Rugge M; Grigioni W; Bencardino K; Lonardi S; Zagonel V; Leone F; Noe J; Ciardiello F; Pinto C; Labianca R; Mosconi S; Graiff C; Aprile G; Frau B; Garufi C; Loupakis F; Racca P; Tonini G; Lauricella C; Veronese S; Truini M; Siena S; Marsoni S; Gambacorta M
Mod Pathol; 2015 Nov; 28(11):1481-91. PubMed ID: 26449765
[TBL] [Abstract][Full Text] [Related]
16. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Sclafani F; Roy A; Cunningham D; Wotherspoon A; Peckitt C; Gonzalez de Castro D; Tabernero J; Glimelius B; Cervantes A; Eltahir Z; Oates J; Chau I
Ann Oncol; 2013 Dec; 24(12):3123-8. PubMed ID: 24146218
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S; El-Sabban M; Doughan S; Abou-Kheir W
World J Gastroenterol; 2023 Mar; 29(9):1395-1426. PubMed ID: 36998426
[TBL] [Abstract][Full Text] [Related]
18. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer.
Dazio G; Epistolio S; Frattini M; Saletti P
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556139
[TBL] [Abstract][Full Text] [Related]
19. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Berlin J; Tolcher AW; Ding C; Whisenant JG; Horak ID; Wood DL; Nadler PI; Hansen UH; Lantto J; Skartved NJØ; Pedersen MW; Patnaik A
Invest New Drugs; 2022 Jun; 40(3):586-595. PubMed ID: 35113285
[TBL] [Abstract][Full Text] [Related]
20. Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.
Guarini C; Grassi T; Pezzicoli G; Porta C
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34202896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
